This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Zumutor Biologics Inc.
OncoNano Medicine, Inc.
Compass Therapeutics
Nurix Therapeutics, Inc.
Seagen Inc.
Corvus Pharmaceuticals, Inc.
Fred Hutchinson Cancer Center
AstraZeneca
M.D. Anderson Cancer Center
Incyte Corporation
Tocagen Inc.
Lytix Biopharma AS